Omeros Corporation (NASDAQ:OMER) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Omeros Corporation (NASDAQ:OMER) have received an average rating of “Moderate Buy” from the five research firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $33.6667.

A number of brokerages recently commented on OMER. D. Boral Capital reissued a “buy” rating and issued a $36.00 price target on shares of Omeros in a report on Monday, December 1st. Wall Street Zen lowered Omeros from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research report on Wednesday, October 15th. HC Wainwright lifted their price target on shares of Omeros from $9.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, October 15th. Finally, WBB Securities reaffirmed a “strong-buy” rating and issued a $45.00 price target on shares of Omeros in a report on Wednesday, October 15th.

Hedge Funds Weigh In On Omeros

A number of hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in Omeros by 3.0% in the first quarter. Vanguard Group Inc. now owns 3,237,256 shares of the biopharmaceutical company’s stock valued at $26,610,000 after buying an additional 95,599 shares during the last quarter. Deutsche Bank AG grew its position in shares of Omeros by 4.9% in the 1st quarter. Deutsche Bank AG now owns 42,019 shares of the biopharmaceutical company’s stock worth $345,000 after acquiring an additional 1,973 shares in the last quarter. Invesco Ltd. grew its position in shares of Omeros by 169.1% in the 1st quarter. Invesco Ltd. now owns 87,044 shares of the biopharmaceutical company’s stock worth $716,000 after acquiring an additional 54,696 shares in the last quarter. Nuveen LLC bought a new stake in shares of Omeros in the 1st quarter valued at approximately $938,000. Finally, Wellington Management Group LLP acquired a new stake in shares of Omeros during the 1st quarter valued at approximately $1,118,000. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Omeros Trading Down 1.6%

OMER opened at $10.85 on Monday. Omeros has a twelve month low of $2.95 and a twelve month high of $13.60. The firm has a market cap of $769.27 million, a price-to-earnings ratio of -5.37 and a beta of 2.48. The company has a fifty day simple moving average of $7.37 and a 200 day simple moving average of $5.03.

Omeros (NASDAQ:OMER) last posted its quarterly earnings data on Thursday, November 13th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.39. On average, analysts forecast that Omeros will post -3.09 earnings per share for the current fiscal year.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.